Inhibitors of mtor-deptor interactions and methods of use thereof
AssigneesThe Regents of the University of California, The United States Government as represented by the Department of Veterans Affairs
InventorsAlan Lichtenstein, Michael E. Jung, Joseph F. Gera, Jihye Lee, Yijiang Shi
Life of this patent
Estimating the term…
Abstract
Provided herein are substituted hydrazone compounds useful as inhibitors of DEPTOR. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted hydrazone compounds.
Claims44
The compound of claim 1, wherein the compound has a structure of Formula I
- wherein
- A is optionally substituted amino, alkylamino, cycloalkylamino, heterocyclylamino,
- arylamino, heteroarylamino, acylamino, diacylamino, or
- R1, R2, R3, and R4 are each, independently for each occurrence, H, halo or optionally substituted alkyl;
- and
- R5 is, independently for each occurrence, H or optionally substituted alkyl.
The compound of any preceding claim, wherein R2 is halo.
The compound of any preceding claim, wherein R3 is halo.
The compound of any preceding claim, wherein R4 is halo.
The compound of any preceding claim, wherein R1, R2, R3, and R4 are each halo, preferably each F or Cl.
The compound of any preceding claim, wherein A is —NHR6 or —NR6R7;
- R6 and R7 are each, independently for each occurrence, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
A pharmaceutical composition comprising a compound of any preceding claim and pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.